EML4‐ALK V3 in NSCLC is associated with a relatively poor response to ALK inhibitors and more aggressive metastatic disease than longer EML4‐ALK variants such as V1 (Woo et al, 2017; Christopoulos et al, 2018, 2019). Here, ALK is linked to metastatic neoplasm.